Sutter Health Palo Alto Center
Palo Alto, California, 94301, United States
NCT Number: NCT07074158
We aim at identifying potential biomarkers in plasma indicative of post-acute coronavirus SARS-CoV-2 Syndrome (Long COVID). Our case-control study will compare Long COVID patients to healthy patients from Sutter Health.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Palo Alto, California, 94301, United States
Two measures will be obtained from participants' plasma:
The diagnostic utility of the potential biomarkers, including signatures derived from microbial cell-free DNA fragments found in plasma and plasma cytokines, will be evaluated independently and in various combinations to determine whether and to what extent we can accurately identify Long COVID patients. Moreover, we plan to leverage the Karius Test and the underlying Karius microbial cell-free DNA technology to determine whether there is evidence of more frequent reactivations of latent infections in patients with long COVID compared to matched healthy control. Plasma samples will also be stored for future comparative studies of additional immune profiles.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
In this proof-of-concept study, we want to test the hypothesis that mcfDNA has diagnostic utility as a biomarker for long COVID patients by applying the agnostic metagenomic sequencing approach.
Time frame: Baseline
Cytokine signatures have been associated with disease severity in patients with chronic fatigue syndrome (Montoya et al, Proc Natl Acad Sci U S A. 2017 Aug 22;114(34): E7150-E7158.). We want to test the hypothesis that cytokine profiles may serve as surrogate biomarkers for Long COVID.
Time frame: Baseline
Analysis of microbial-cell-free DNA and cytokine to identity meta-signatures associated with Long COVID and/or Long COVID severity.
Palo Alto Medical Foundation
Other
Identification of Microbial and Cytokine Signatures in Long COVID Patients: A Case-control Study of Long COVID Patients With Healthy Individuals
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06086379
COVID-19, Chronic Disease
San Diego, California, United States
View Trial DetailsNCT07388550
COVID-19, Chronic Disease
Bethesda, Maryland, United States
View Trial DetailsNCT07005921
Behavior, Behavioral Symptoms
Macaíba, Rio Grande do Norte, Brazil
View Trial DetailsNCT05421208
Autonomic Nervous System Diseases, COVID-19
Nashville, Tennessee, United States
View Trial Details